<DOC>
	<DOCNO>NCT02428400</DOCNO>
	<brief_summary>Methodology : This double-blind , randomize , placebo-controlled , multi-cohort Phase 1/1b study patient currently treat chronic HBV infection . For cohort , patient must receive antiviral treatment either tenofovir disoproxil fumarate ( TDF ) entecavir ( ENT ) least two year , HBV infection well-controlled</brief_summary>
	<brief_title>Safety Tolerability TG1050 : A Dose-finding Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>18 65 year age , inclusive Patients must undetectable neutralize antibody Adenovirus serotype 5 ( Ad5 ) ( PART A ONLY ) Negative serum βHCG ( woman childbearing potential ; woman nonchildbearing potential define woman postmenopausal ≥ 2 year hysterectomy , bilateral oophorectomy , medically document ovarian failure ) Female patient childbearing potential must willing use double effective method contraception ( e.g . two follow : hormonal contraception , condom occlusive cap , intrauterine device ( IUD ) intrauterine system ( IUS ) , male sterilisation , true abstinence ) 3 month last IMP administration ; male patient must agree use double effective method contraception ( e.g . two follow : hormonal contraception , condom occlusive cap , IUD IUS , male sterilisation , true abstinence ) heterosexual intercourse partner capable become pregnant throughout 3 month last IMP administration Currently treatment HBV monoinfection ( HBV genotype ) least 2 year either nucleos ( ) ide analogue TDF ENT A history HBV DNA &lt; 20 IU/mL least 6 month entry HBV DNA &lt; 20 IU/mL screening . HBsAg positive HBeAg positive HBeAg negative patient HBV infection Compensated liver disease ; define direct conjugate bilirubin ≤ 1.2 × ULN , PT/INR ≤ 1.2 × ULN , platelets ≥ 150,000/mm3 , serum albumin ≥ 3.5 g/L , prior history clinical hepatic decompensation ( eg , ascites , jaundice , encephalopathy , variceal hemorrhage ) ALT ≤ ULN . Due biological variability , retest ALT parameter allow ALT value screen exceed 10 % ULN value eligibility criterion meet . In case , ALT retest perform one month initial ALT screen assay confirm within 2 week . Values two ALT assay retests equal ULN include patient . In case retest ALT parameter , hematology biochemistry parameter reassess parallel second ALT retest ensure still match TG1050.02 eligibility criterion . Hemoglobin ≥ 10 g/L Creatinine clearance &gt; 50mL/min Neutrophils ≥ 1,500/mm3 Signed , write Independent Ethics Committee ( IEC ) approve informed consent Patients evidence hepatocellular carcinoma liver cancer Patients αfetoprotein &gt; 50 ng/mL Patients coinfected human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) hepatitis Delta virus ( HDV ) Patients either ) medical history evidence cirrhosis biopsy show cirrhosis approve noninvasive test indicative cirrhosis document medical source document ; OR b ) either follow screening : transient elastography score ≥ 10.5 kPa OR Fibrotest® Fibrosure® score ≥ 0.48 aspartate aminotransferase platelet ratio Index ( APRI ) ≥1 . Note : If biopsy noninvasive test never perform biopsy noninvasive test perform showed cirrhosis , b ) must follow screen Patients history uncontrolled thyroid disease abnormal thyroid stimulate hormone ( TSH ) level screen ( define &lt; 0.8 × low limit normal [ LLN ] &gt; 1.2 × ULN ; patient eligible abnormal TSH level free triiodothyronine ( FT3 ) free thyroxine ( FT4 ) within normal limit ) Significant concomitant medical disorder include active systemic infection proven suspect immunosuppressive disorder History immunodeficiency autoimmune disease ( include autoimmune hepatitis , preexist autoimmune antibodymediated disease ) Current history clinically significant oncologic , pulmonary , hepatic , gastrointestinal , renal , cardiovascular , metabolic , endocrine , neurologic , hematologic illness , major organ transplantation , major medical disorder , judgment investigator , would interfere patient treatment , preclude patient participation study ; discuss case case Sponsor Pregnant breastfeed woman Prior treatment experimental gene therapy product gene therapy product Prior participation another research protocol involve investigation medicinal product ( IMP ) within 4 month prior TG1050/placebo injection History substance abuse , include alcohol abuse judgment investigator would deem patient suitable participation study Patients unable unwilling comply protocol requirement All key inclusion exclusion criterion remain patient Part A , MD Cohort Part B study except follow : Patients detectable undetectable antiAd5 neutralize antibody eligible ( i.e . regardless preimmunity Ad5 nAb ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>